BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their RightsShareholders should contact the firm immediately as there may be limited time to enforce your rights
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (
NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology RaceLarge pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant to enter the oncology race with its $1.4 billion acquisition of Point Biopharma Global, a company specializing in precise radioligand therapies for cancer. Earlier this year, Pfizer … Continue reading "Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race"
